钠-葡萄糖共转运蛋白 2 抑制剂相关的血糖正常糖尿病酮症酸中毒在一位糖尿病前期患者的原位心脏移植后：病例报告。
Sodium-Glucose Cotransporter-2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis After Orthotopic Heart Transplant in a Prediabetic Patient: A Case Report.
机构信息
Department of Medicine, University of California at Los Angeles, Los Angeles, California.
Department of Pharmacy, University of California at Los Angeles, Los Angeles, California.
出版信息
Transplant Proc. 2021 Oct;53(8):2636-2639. doi: 10.1016/j.transproceed.2021.08.017. Epub 2021 Sep 13.
Postoperative euglycemic diabetic ketoacidosis (euDKA) associated with sodium-glucose cotransporter-2 (SGLT2) inhibitor use has been well-documented and carries a Food and Drug Administration recommendation to hold SGLT2 inhibitors 3 to 4 days before a planned surgical procedure. Unfortunately, many surgical procedures, such as orthotopic heart transplant (OHT), are unplanned and unpredictable. With the increasing use of SGLT2 inhibitors in diabetic and non-diabetic heart failure patients, new challenges in patient management and perioperative risk have arisen. We report a case in which SGLT2 inhibitor-associated euDKA complicated the postoperative course of a prediabetic patient who had undergone OHT.
术后血糖正常的糖尿病酮症酸中毒（euDKA）与钠-葡萄糖共转运蛋白-2（SGLT2）抑制剂的使用有关，已被充分记录在案，并得到美国食品和药物管理局（FDA）的建议，即在计划进行手术前 3 至 4 天停止使用 SGLT2 抑制剂。不幸的是，许多手术，如原位心脏移植（OHT），都是非计划性和不可预测的。随着 SGLT2 抑制剂在糖尿病和非糖尿病心力衰竭患者中的应用日益增多，患者管理和围手术期风险方面出现了新的挑战。我们报告了一例 SGLT2 抑制剂相关的 euDKA 病例，该病例使一位接受 OHT 的糖尿病前期患者的术后病程复杂化。
Zotero 插件